Human papillomavirus 16 E6 increases the radiosensitivity of p53-mutated cervical cancer cells, associated with up-regulation of aurora A

International Journal of Radiation Biology

Volumn 86, Issue 9, 2010, Pages 769-779

  Shin, Hye Jin ^a   Kim, Joo Young ^a   Hampson, Lynne ^b   Pyo, Hongryull ^a   Baek, Hye Jung ^a   Roberts, Stephen A ^b   Hendry, Jolyon H ^c   Hampson, Ian N ^b  

^a National Cancer Center   (South Korea)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Adlington   (United Kingdom)

Author keywords

aurora A; cervical cancer; Human papillomavirus (HPV) 16 E6; p53; radiosensitivity

Indexed keywords

AURORA KINASE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; H2AFX PROTEIN, HUMAN; HISTONE; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE; REPRESSOR PROTEIN; SMALL INTERFERING RNA;

ANTAGONISTS AND INHIBITORS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MUTATION; PATHOLOGY; PHYSIOLOGY; POLYPLOIDY; RADIATION DOSE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; UPREGULATION; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

AURORA KINASES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, P53; HISTONES; HUMANS; MUTATION; ONCOGENE PROTEINS, VIRAL; POLYPLOIDY; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 77956286736     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2010.484477     Document Type: Article

References (28)

1. Chen SS, Chang PC, Cheng YW, Tang FM, Lin YS. 2002. Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function. EMBO Journal 21:4491-4499.
2. Chng WJ, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R, Dogan A, Fonseca R. 2008. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 111:1603-1609.
3. Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH. 1992. Clonal p53 mutation in primary cervical cancer: Association with human-papillomavirus- negative tumours. The Lancet 339:1070-1073.
4. Crook T, Wrede D, Vousden KH. 1991. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 6:873-875.
5. Datta NR, Kumar P, Singh S, Gupta D, Srivastava A, Dhole TN. 2006. Does pretreatment human papillomavirus (HPV) titers predict radiation response and survival outcomes in cancer cervix? A pilot study. Gynecologic Oncology 103:100-105.
6. Feki LA. 2006. Phenotypic features with p53 alterations related to human papillomavirus and prognostic evaluation in cervical cancer. International Journal of Gynecological Cancer 16:708-717.
7. Ferguson BE, Oh DH. 2005. Proficient global nucleotide excision repair in human keratinocytes but not in fibroblasts deficient in p53. Cancer Research 65:8723-8729.
8. Ford JM, Baron EL, Hanawalt PC. 1998. Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation. Cancer Research 58:599-603.
9. Giampieri S, Storey A. 2004. Repair of UV-induced thymine dimers is compromised in cells expressing the E6 protein from human papillomaviruses types 5 and 18. British Journal of Cancer 90:2203-2209.
10. Hampson L, El Hady ES, Moore JV, Kitchener H, Hampson IN. 2001. The HPV16 E6 and E7 proteins and the radiation resistance of cervical carcinoma. Faseb Journal 15:1445-1447.
11. Harima Y, Sawada S, Nagata K, Sougawa M, Ohnishi T. 2002. Human papilloma virus (HPV) DNA associated with prognosis of cervical cancer after radiotherapy. International Journal of Radiation Oncology Biology Physics 52:1345-1351.
12. Helland A, Karlsen F, Due EU, Holm R, Kristensen G, Borresen-Dale A. 1998. Mutations in the TP53 gene and protein expression of p53,MDM2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load. British Journal of Cancer 78:69-72.
13. Higgins GD, Davy M, Roder D, Uzelin DM, Phillips GE, Burrell CJ. 1991. Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA. The Lancet 338:910-913.
14. Ishikawa H, Mitsuhashi N, Sakurai H, Maebayashi K, Niibe H. 2001. The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with stage IIIB cervical carcinoma treated with radiation therapy alone. Cancer 91:80-89.
15. Kim JY, Kim CH, Stratford IJ, Patterson AV, Hendry JH. 2004. The bioreductive agent RH1 and gamma-irradiation both cause G2/M cell cycle phase arrest and polyploidy in a p53-mutated human breast cancer cell line. Radiation Oncology Biology Physics 58:376-385.
16. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nuñez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G; Nomenclature Committee on Cell Death 2009. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009 Jan;16(1):3-11. Epub 2008 Oct 10.
17. Liu Y, Heilman SA, Illanes D, Sluder G, Chen JJ. 2007. p53-independent abrogation of a postmitotic checkpoint contributes to human papillomavirus E6-induced polyploidy. Cancer Research 67:2603-2610.
18. Lu X, Feki A. 2006. Phenotypic features with p53 alterations related to human papillomavirus and prognostic evaluation in cervical cancer. International Journal of Gynecological Cancer 16:708-717.
19. Marumoto T, Zhang D, Saya H. 2005. Aurora-A - a guardian of poles. Nature Reviews Cancer 5:42-50.
20. Paquette RL, Lee YY, Wilczynski SP, Karmakar A, Kizaki M, Miller CW, Koeffler HP. 1993. Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer 72:1272-1280.
21. Riou G, Favre M, Jeannel D, Bourhis J, Le Doussal V, Orth G. 1990. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. The Lancet 335:1171-1174.
22. Sisk EA, Bradford CR, Jacob A, Yian CH, Staton KM, Tang G, Harris MO, Carey TE, Lancaster WD, Gregoire L. 2000. Human papillomavirus infection in young versus old patients with squamous cell carcinoma of the head and neck. Head and Neck 22:649-657.
23. Sisk EA, Soltys SG, Zhu S, Fisher SG, Carey TE, Bradford CR. 2002. Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head and Neck 24:841-849.
24. Song S, Gulliver GA, Lambert PF. 1998. Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proceedings of the National Academy of Sciences of USA 95:2290-2295.
25. Tao Y, Zhang P, Frascogna V, Lecluse Y, Auperin A, Bourhis J, Deutsch E. 2007. Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. British Journal of Cancer 97:1664-1672.
26. Teoh NC, Dan YY, Swisshelm K, Lehman S, Wright JH, Haque J, Gu Y, Fausto N. 2008. Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice. Hepatology 47:2078-2088.
27. Thompson DA, Belinsky G, Chang TH, Jones DL, Schlegel R, Munger K. 1997. The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints. Oncogene 15:3025-3035.
28. Zhang H, Jin Y, Chen X, Jin C, Law S, Tsao SW, Kwong YL. 2007. Papillomavirus type 16 E6/E7 and human telomerase reverse transcriptase in esophageal cell immortalization and early transformation. Cancer Letters 245:184-194.